Mutual of America Capital Management LLC trimmed its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 36.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,651 shares of the biopharmaceutical company’s stock after selling 27,415 shares during the period. Mutual of America Capital Management LLC’s holdings in ACADIA Pharmaceuticals were worth $1,795,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Elliott Management Corp raised its holdings in shares of ACADIA Pharmaceuticals by 61.7% during the 2nd quarter. Elliott Management Corp now owns 1,256,795 shares of the biopharmaceutical company’s stock worth $35,052,000 after acquiring an additional 479,413 shares in the last quarter. York Capital Management Global Advisors LLC purchased a new stake in shares of ACADIA Pharmaceuticals during the 2nd quarter worth approximately $3,347,000. State Street Corp raised its holdings in shares of ACADIA Pharmaceuticals by 15.8% during the 2nd quarter. State Street Corp now owns 3,748,468 shares of the biopharmaceutical company’s stock worth $104,551,000 after acquiring an additional 510,670 shares in the last quarter. Palo Alto Investors LLC raised its holdings in shares of ACADIA Pharmaceuticals by 1.4% during the 2nd quarter. Palo Alto Investors LLC now owns 1,613,330 shares of the biopharmaceutical company’s stock worth $44,996,000 after acquiring an additional 22,900 shares in the last quarter. Finally, Janus Henderson Group PLC purchased a new stake in shares of ACADIA Pharmaceuticals during the 2nd quarter worth approximately $102,152,000. 96.97% of the stock is currently owned by institutional investors and hedge funds.

Several analysts have recently issued reports on the company. Zacks Investment Research cut ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, October 16th. Jefferies Group LLC reaffirmed a “buy” rating and set a $47.00 price objective on shares of ACADIA Pharmaceuticals in a report on Thursday, October 12th. Leerink Swann reaffirmed a “market perform” rating on shares of ACADIA Pharmaceuticals in a report on Monday, October 9th. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and set a $45.00 price objective on shares of ACADIA Pharmaceuticals in a report on Friday, October 6th. Finally, J P Morgan Chase & Co set a $50.00 price objective on ACADIA Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, October 5th. Six equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $47.73.

In related news, EVP Glenn Baity sold 26,507 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $34.87, for a total transaction of $924,299.09. Following the transaction, the executive vice president now owns 94,163 shares in the company, valued at $3,283,463.81. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In the last quarter, insiders have sold 78,329 shares of company stock worth $2,957,975. 22.25% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: “Mutual of America Capital Management LLC Sells 27,415 Shares of ACADIA Pharmaceuticals Inc. (ACAD)” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://theolympiareport.com/2017/11/02/mutual-of-america-capital-management-llc-sells-27415-shares-of-acadia-pharmaceuticals-inc-acad.html.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.55) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.72) by $0.17. ACADIA Pharmaceuticals had a negative return on equity of 62.08% and a negative net margin of 485.14%. The firm had revenue of $30.50 million for the quarter, compared to the consensus estimate of $20.02 million. During the same quarter last year, the business posted ($0.63) earnings per share. The firm’s revenue was up 30400.0% compared to the same quarter last year.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).

Want to see what other hedge funds are holding ACAD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD).

Institutional Ownership by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.